NASDAQ:WHWK Whitehawk Therapeutics (WHWK) Stock Price, News & Analysis $1.72 -0.08 (-4.44%) As of 08/7/2025 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsSEC FilingsTrendsBuy This Stock About Whitehawk Therapeutics Stock (NASDAQ:WHWK) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Whitehawk Therapeutics alerts:Sign Up Key Stats Today's Range$1.71▼$1.7850-Day Range N/A52-Week Range$1.21▼$3.81Volume21,875 shsAverage Volume94,156 shsMarket Capitalization$81.03 millionP/E Ratio10.75Dividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California. Read More Receive WHWK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Whitehawk Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address WHWK Stock News HeadlinesWhitehawk Therapeutics Reports Second Quarter 2025 Financial Results and Recent HighlightsAugust 7 at 8:00 AM | prnewswire.comWhitehawk Therapeutics to Participate in the BTIG Virtual Biotechnology ConferenceJuly 22, 2025 | prnewswire.comSee More Headlines WHWK Stock Analysis - Frequently Asked Questions How have WHWK shares performed this year? Whitehawk Therapeutics' stock was trading at $1.87 at the beginning of the year. Since then, WHWK stock has decreased by 8.0% and is now trading at $1.72. How were Whitehawk Therapeutics' earnings last quarter? Whitehawk Therapeutics, Inc. (NASDAQ:WHWK) posted its earnings results on Thursday, August, 7th. The company reported ($0.76) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.49 by $1.25. Whitehawk Therapeutics had a net margin of 99.42% and a negative trailing twelve-month return on equity of 56.73%. How do I buy shares of Whitehawk Therapeutics? Shares of WHWK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Today8/07/2025Last Earnings8/07/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorManufacturing Industry Pharmaceutical Preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:WHWK CIK1422142 WebN/A Phone(424) 473-8055FaxN/AEmployees40Year FoundedN/AProfitability EPS (Trailing Twelve Months)$0.16 Trailing P/E Ratio10.75 Forward P/E RatioN/A P/E GrowthN/ANet Income-$63.69 million Net Margins99.42% Pretax Margin99.42% Return on Equity-56.73% Return on Assets-48.68% Debt Debt-to-Equity RatioN/A Current Ratio18.95 Quick Ratio18.95 Sales & Book Value Annual Sales$25.98 million Price / Sales3.12 Cash FlowN/A Price / Cash FlowN/A Book Value$2.12 per share Price / Book0.81Miscellaneous Outstanding Shares47,110,000Free Float23,602,000Market Cap$81.03 million OptionableN/A Beta0.55 The Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free Report This page (NASDAQ:WHWK) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredAmazon’s big Bitcoin embarrassmentBitcoin just passed Amazon in total market cap — but most investors are missing the bigger opportunity. Whi...Brownstone Research | SponsoredCritical AI announcement set to ignite AI 2.0 A new 100% tariff on imported chips just rattled the tech sector—sending some stocks soaring and others tumbli...Timothy Sykes | SponsoredTrump’s new nightmareAccording to Porter Stansberry and Jeff Brown, a government-led financial mobilization is already reshaping Am...Porter & Company | SponsoredThe Day Silicon DiesThe Day China Left America's Supercomputers in the Dust In 200 seconds, China's quantum computer accomplish...The Oxford Club | SponsoredThis accelerated income plan is solving American's #1 retirement fearThe #1 fear in retirement today? Running out of money. That’s why income expert Tim Plaehn created a simple...Investors Alley | SponsoredSell this, buy thatWhat you don’t own matters just as much as what you do. That’s the thinking behind Eric Fry’s long-time strate...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Whitehawk Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Whitehawk Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.